Cleveland, Ohio – October 6, 2025 – Crain’s Cleveland Business Fast 50 list spotlights rapidly growing, privately held companies ranked by revenue growth over the last five years. SPR was recognized as the fastest growing company in the initial 2024 program and sustained an amazing rate of growth, ranking #2 on the list in 2025. SPR achieved revenue growth of nearly 500% thanks to the use and adoption of the SPRINT® PNS System in the last five years.
Maria Bennett, President, CEO, and Founder of SPR shared,
“To see our company in the top performers two years in a row amongst impressive and rapidly growing companies in our region is very rewarding. Sustaining rapid acceleration in growth like we have through a pandemic, commercial expansion, and building a new market for pain treatments is a testament to our team meeting the needs of our customers and working to transform the lives of patients.”
This recognition follows Top Workplaces USA and Northeast Ohio Top Workplaces awards along with leadership honors for SPR® senior management, highlighting the connection of corporate culture and business achievement.
About the SPRINT PNS System
The SPR® SPRINT® PNS System marks an innovative shift in the treatment of pain. Our breakthrough, 60-day treatment is a First-Line PNS™ option uniquely proposed to recondition the central nervous system to provide significant and sustained relief from chronic pain — without a permanent implant, nerve destruction or the risk of addiction. The system has been studied extensively for low back pain, knee pain, shoulder pain, post-amputation pain, and chronic and acute postoperative pain, is cleared for use up to 60 days, and is recognized by leading pain management centers. Market research indicates that this breakthrough neuromodulation treatment is a patient-preferred alternative to more invasive options.
The SPRINT PNS System is indicated for up to 60 days for: Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; symptomatic relief of post-traumatic pain; symptomatic relief of postoperative pain. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves.
Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.
For additional information regarding safety and efficacy, visit: SPR Safety Information.
About SPR
SPR is a privately held medical device company, providing patients with a non-opioid, minimally invasive pain treatment option. Our SPRINT® PNS System fulfills a critical unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain. Backed by the largest body of clinical evidence in peripheral nerve stimulation for the treatment of pain, SPR has demonstrated commercial demand in untapped peripheral (shoulder and knee) and back pain markets and built an incredibly strong foundation for commercial growth. Headquartered in Cleveland, OH with satellite offices in Chapel Hill, NC and Minneapolis, MN, SPR’s Senior Management team includes experienced industry veterans with nearly 200 years of collective pain market and MedTech expertise, all driven by our purpose – to improve the quality of patients’ lives by providing them with a minimally invasive, drug-free, surgery-free solution to manage their acute and chronic pain. SPR – Solutions for pain. Inspired by life.™